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Abstract 
This study aimed to determine if there are
differences  in  inflammatory  markers  in  the
acute phase between systolic heart failure and
heart failure with preserved systolic function.
One  hundred  and  thirty-one  patients  with
acute  heart  failure  were  recruited  consecu-
tively.  At  admission,  plasma  fibrinogen,  C-
reactive  protein,  sialic  acid,  von  Willebrand
factor,  vascular  endothelial  growth  factor,
interleukin-6 and NTproBNP were all evaluat-
ed. If the ejection fraction was 45% or over
patients were included in the HF-PSF group;
the remaining patients were included in the
SHF group. The HF-PSF patients were older
(72±10 vs 63±12 years, P<0.001), presented a
higher rate of atrial fibrillation (56.1 vs 21.3%,
P<0.001), and had a lower rate of hemoglobin
(12.2±2 vs 13.3±2.1 g/dL, P<0.01). No signifi-
cant differences were observed in the inflam-
mation markers analyzed among SHF and HF-
PSF groups. In the acute phase of heart failure
there is a marked elevation of inflammatory
markers but there are no differences in the
inflammatory markers analyzed between the
two different types of heart failure.
Introduction
Heart failure (HF) is currently one of the
most prevalent diseases and it inflicts a con-
siderable economic burden on the health care
system.1 Until a few years ago, attention was
only paid to HF with depressed systolic func-
tion (SHF). It was not until quite recently that
an interest in HF with preserved systolic func-
tion (HF-PSF) has been shown.2
Despite the fact that HF-PSF represents 50% of
the population with HF,3,4 few specific studies
have been conducted in clinical, prognostic,
and treatment terms. This implies assuming
that what we know about SHF applies to HF-
PSF.  Nonetheless,  there  are  some  studies
which prove that the two types of HF differ.
Thanks to a number of studies, an improved
prognosis in SHF has been observed in recent
years, while there has been no such improve-
ment in the field of HF-PSF given the lack of
specific studies. Inflammation has generally
been shown to play a key role in HF, particular-
ly  in  SHF.5 In  these  patients,  an  increased
inflammation  status  occurs  in  the  stable
phase of the disease. This increases in the
decompensation  periods.  This  inflammation
contributes not only to the central and periph-
eral manifestations of the disease, but also to
the persistence of the disease. Certain inflam-
matory  markers  (IM)  of  a  prognostic  value
have been identified. Some of them have even
been shown to have a clinical use,6,7 like brain
natriuretic peptide (BNP) and its non-active
aminoterminal  fragment  NTproBNP.  On  the
other hand, there have been very few studies
of inflammatory status in HF-PSF patients.8
HF studies generally tend to cover only one
type of HF; very few have covered both. As a
result, only a few studies have compared SHF
with  HF-PSF,  and  even  fewer  studies  have
been concerned with research into inflamma-
tion. To date, there has been only one article
comparing  several  IM  in  stable  patients  in
terms of HF type.8
The objective of this study was to assess the
levels of specific IM in patients who had been
diagnosed  with  acute  HF  while  hospitalized
according to the type of HF presented (SHF vs
HF-PSF). 
Materials and Methods
Study population 
From  September  2006  to  November  2007,
155  patients  diagnosed  with  acute  HF  and
admitted to the Cardiology Unit were consecu-
tively enrolled. HF diagnosis was made accord-
ing to the patients’ signs and symptoms and to
the Framingham criteria.9 All the patients had
a functional NYHA class of III or over. HF etiol-
ogy was based on medical records and on the
results of complementary tests. Patients who
had been previously hospitalized, had under-
gone  coronary/heart  surgery  three  months
prior to being admitted to the Cardiology Unit,
or had not signed the informed consent, were
excluded from the study. A total number of 131
patients went forward for analysis (SHF n=62,
HFPSF n=69).
This study was carried out in accordance
with the Declaration of Helsinki. It was also
approved by the Biomedical Research Ethics
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Committee at the University La Fe Hospital. All
the patients gave their written informed con-
sent to participate in this study. 
Variables and complementary tests
High blood pressure, dyslipidemia and dia-
betes were considered when patients were pre-
scribed drugs to control these risk factors.
An electrocardiogram was performed for all
patients upon arrival. An echocardiography was
performed within 48 h of hospital admission to
rule  out  transient  systolic  dysfunction.  The
equipment used was an HP Sonos 5500® with a
2.5  MHz  probe  (Philips,  Eindhoven,  The
Netherlands).  All  the  readings,  including  the
ejection fraction (EF), were taken according to
the recommendations of the American Society
of Echocardiography.10 If the EF was below 45%,
the  patient  was  included  in  the  SHF  group,
while the remaining patients were included in
the HF-PSF group. Coronary catheterization was
performed in those patients who had not previ-
ously undergone the procedure, or who had had
this performed more than one year before.
Markers and biochemical determi-
nations
In an attempt to minimize the influence of
the  treatment,  blood  samples  were  obtained
from all patients within 24 h of hospital admis-
sion.  IM  included  were:  plasma  fibrinogen
(PF),  C-reactive  protein  (CRP),  sialic  acid
(SA),  von  Willebrand  factor  (vWF),  vascular
endothelial growth factor VEFG, interleukin-6
(IL-6), and NTproBNP. PF levels were obtained
by measuring the plasma fibrin formation rate
by a turbidity assay. The coefficient of varia-
tion was 8%. CRP plasma levels were measured
by nephelometry using a commercial high sen-
sitivity assay (Dade-Behring, Germany). The
coefficient of variation was 4.3%. Total SA plas-
ma levels were measured using a commercial
enzymatic-colorimetric  method  (Sialic  acid
Farbtest,  Boehringer  Mannheim,  Germany).
The coefficient of variation was 3.6%. As an
endothelial dysfunction marker, vWF antigen
levels  were  measured  in  an  ACL-TOP  (3G)
(Instrumentation Laboratory) using latex par-
ticles coated with a polyclonal antibody direct-
ed  against  vWF.  The  coefficient  of  variation
was 7.5%. As well as the angiogenesis markers,
total serum levels of VEGF were determined by
ELISA according to the manufacturer’s instruc-
tions  (VEGF  Biosource  International).  The
coefficient of variation was 4.9%. IL-6 serum
levels were determined by ELISA method (High
Sensitivity Human IL-6 ELISA kit, Diaclone).
The  coefficient  of  variation  was  3.6%.  NT-
proBNP  was  measured  by  electrochemilumi-
nescence immunoassays in an Elecsys® 2010
analyzer  (Roche  Diagnostics,  Mannheim,
Germany).
Statistical analysis
The continuous variables were expressed as
mean  ±  standard  deviation.  Student’s  t-test
was used to analyze the quantitative variables,
while the c2 test was performed to analyze the
qualitative  variables.  Pearson’s  correlation
was performed for correlations. The normality
of IM was verified by the Kolmogorov-Smirnov
test and the Mann-Whitney U-test. The statis-
tical package used was SPSS®, v. 15.0 (SPSS
Inc. Chicago, Ill, USA).
Results
Baseline characteristics
Patients’ baseline characteristics and treat-
ments are shown in Tables 1 and 2, respective-
ly.  SHF  patients  were  significantly  older
(72±10 vs 63±12 years, P<0.001). The HF-PSF
group  included  more  non-smokers  (73.9  vs
38.7%,  P<0.001),  and  patients  presented  a
higher rate of atrial fibrillation (56.1 vs 21.3%,
P<0.001). Among the etiologies, valvular (46.4
vs11.5%, P<0.001) and hypertensive etiologies
(20.3 vs 8.2%, P<0.001) were more frequent in
HF-PSF  patients,  while  ischemic  (39.2  vs
20.3%,  P<0.001)  and  idiopathic  dilated  car-
diomyopathy  etiologies  (26.2  vs 1.4%,
P<0.001) were more frequent in SHF patients.
EF  was  lower  in  the  SHF  group  (28±9  vs
57±4%, P<0.001) and the end diastolic diame-
ter was higher (63±9 vs 49±7 mm, P<0.001).
Differences in patients’ basal treatment were
related to their basic pathologies; nonetheless,
acetylsalicylic  acid  was  the  most  frequent
treatment  in  the  SHF  group  (46.6  vs 28.4;
P<0.05),  and  anticoagulants  (24.1  vs 44.8%;
P<0.05)  and  calcium  antagonists  (15.5  vs
34.3%; P<0.05) were the most frequent treat-
ment in the HF-PSF group. 
Of the general analytical data (Table 1), only
hemoglobin was significantly lower in the HF-
PSF patient group (12.2±2 vs 13.3±2.1 g/dL,
P<0.01).  No  differences  were  found  in  the
remaining ordinary analytical values, includ-
ing the Quick Index or creatinine.
Inflammatory markers
No significant inter-group differences were
found in the IM analyzed (Table 3); only a high
VEGF  tendency  was  found  among  the  SHF
patients (424±323 vs 337±263 pg/mL, P<0.1).
We  performed  an  analysis  between  the
Table 1. Basal characteristics.
Total HF (n=131) SHF (n=62) HF-PSF (n=69)
Sex male (%)* 59 77 42
Age (years)* 68±11 63±12 72±10
AHT (%) 72.5 72.6 72.5
Dyslipidemia (%)* 48.9 58.1 40.6
Diabetes (%) 37.4 40.3 34.8
Smoking (%)* 
Yes 6.8 9.7 4.3
No 56.8 38.7 73.9
Ex 36.4 51.6 21.7
Permanent AF (%)** 40 21.3 56,5
Etiology (%)*
Ischemic 29.2 39.3 -20.3
IDCM 13.1 26.2 -1.4
Valvular 30.0 11.5 - 46.4
AHT 14.6 8.2 -20.3
Other 13.1 14.9 -1.6
EF (%)** 43±16 28±9 57±4
EDD (mm)** 56±10 63±9 49±7
PsAP (mmHg) 44±18 44±16 45±19
Glucose (mg/dL) 114±41 112±47 115±36
Creatinine (mg/dL) 1.34±0.51 1.38±0.55 1.31±0.48
Total cholesterol (mg/dL) 169±44 168±43 170±45
Total proteins (mg/dL) 6.7±0.8 6.7±0.9 6.7±0.6
Sodium (mEq/L) 138±4 138±4 138±3
Hemoglobin (g/dL)* 12.7±2.1 13.3±2.1 12.2±2.0
Quick index (%) 67±28 68±25 67±30
HF, heart failure; SHF, systolic heart failure; HF-PSF, heart failure with preserved systolic function; AHT, arterial hypertension; FA, atrial fibril-
lation; IDCM, idiopathic dilated cardiomyopathy; EF, ejection fraction; sPAP, systolic pulmonary artery pressure; EDD, end-diastolic diameter;
RV, right ventricle; differences SHF vs. HF-PSF, *P<0.05.**P<0.001.Clinical Investigation
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patients in functional class III (20 patients) or
IV/IV (111 patients) but no significant differ-
ences were found.
Correlations 
SA related inversely and significantly with
the end-diastolic diameter in the HF-PSF group
(r=  -0.375,  P<0.05)  (Table  4).  The  same
occurred in the SH group with hemoglobin (r=
-0.330, P<0.05). We found a positive relation-
ship  between  NTproBNP  and  creatinine  in
both  groups,  particularly  in  the  SHF  group
(r=0.471, P<0.05). Similarly, creatinine asso-
ciated inversely with hemoglobin in both the
SHF  (r=  -0.384,  P<0.05)  and  the  HF-PSF
(r=0.278, P<0.05) groups. 
Discussion
Our results show that there are no signifi-
cant differences in the elevation of certain IM
regarding the type of HF in the acute phase of
HF.  HF  can  be  classified  into  two  groups
according  to  the  EF:  SHF  and  HF-PSF.  Both
groups share many characteristics, but there
are others that clearly differentiate them. Most
of the studies in the field of HF were performed
in patients with SHF. Consequently, while the
prognosis  of  SHF  has  improved  in  the  last
decade, HF-PSF prognosis has seen no such
improvement.
Inflammation plays a key role in the phys-
iopathology of HF and many studies have been
conducted in this area; however, these studies
were mainly on patients in stable phase. These
studies have proven that the elevation of IM is
related to severity.  
The physiopathology of inflammation within
HF is complex, as many elements contribute to
it through the secretion of IM. Thus, in some
studies,  rather  than  focusing  on  identifying
isolated IM as prognostic factors, a combina-
tion of IM has been investigated.11 Therefore,
a wide and varied range of IM have been deter-
mined in the present study with the aim of cov-
ering as many aspects involved in inflamma-
tion as possible.
The  first  conclusion  of  this  study  can  be
drawn from patients’ basal characteristics. As
shown in Tables 1 and 2, differences were con-
cordant with other studies12 and were also log-
ical from a physiopathological point of view. 
Regarding prognosis, that of SHF is worse
than that for HF-PSF in the stable phase, but
prognosis is the same for the two types when
HF-PSF patients are hospitalized.13 Therefore,
prognosis does not only depend on the EF. On
the other hand, and as already proven by our
group,14 inflammation is more related to func-
tional status than to EF. 
As shown in Table 3, IM elevation was sig-
nificant in both groups, and 3-4 times higher
than the values from other studies performed
in patients with stable HF.15
Fibrinogen is a marker which allows explo-
ration of both the general inflammatory status
and the hypercoagulable state. Multiple stud-
ies have associated this to ischemic heart dis-
ease, although it also increases in other heart
pathologies16,17 and in stable phase regardless
of the anticoagulant therapy.18 There were no
differences in the PF, which proves that in this
phase the hypercoagulable state is similar in
both groups.
SA  is  particularly  high  in  patients  with
ischemic  heart  disease.19 Our  group  proved
that SA is also increased in patients with sta-
ble HF of other etiologies,14 as it also occurs in
this study in the acute phase of HF. 
The most sensitive and less specific IM is
the CRP. Some groups consider it to be the IM
paradigm.20 Its chronic and sustained eleva-
tion (>3 mg/dL) has been proven to have neg-
ative prognostic values in multiple diseases,
including HF. CRP is strongly associated with
atherosclerosis and, therefore, to the ischemic
etiology.21 Some studies have shown that there
are  no  differences  in  the  increase  in  CRP
between SHF and HF-PSF in stable phases.22
We  have  found  no  differences  in  the  acute
phase either. This proves, on the one hand, the
non-specificity of CRP, and on the other that an
increase in CRP seems to be more related to
the function status than to the etiology or the
type of HF. 
HF is associated with a marked endothelial
dysfunction and coagulation alterations.23 vWF
is  a  marker  of  endothelial  dysfunction  and
coagulation status. Some studies have demon-
strated  a  marked  elevation  of  vWF  in  HF
patients,24 but to date no comparison has been
made between patients with SHF and HF-PSF.
Nevertheless, we have proved that vWF levels
are  remarkably  high  in  our  sample  and,  in
addition, that there is no relationship between
the EF and the type of HF. Both groups present-
ed a similar Quick index, implying that coagu-
lation  therapy  does  not  seem  to  have  influ-
enced these results. IL-6 is a cytokine that has
been related to the severity of HF and has prog-
nostic value.25,26 IL-6 levels increase with the
functional status of HF patients; therefore, the
levels  presented  herein  were  considerably
higher than those published by other authors
involving  patients  with  stable  HF,  and  were
very similar to the subgroups with worse prog-
nosis.27 The association between IL-6 and the
Table 3.  Comparison of inflammatory markers between both groups.
Total HF (n=131) SHF (n=62) HF-PSF (n=69)
PF (mg/dL) 349±79 348±86 352±71
CRP (mg/L) 37.2±47.5 36.0±46.4 38.8±48.9
SA (mg/dL) 71.8±16.8 71.6±18.2 72.3±15.7
vWF (%) 331±127 318±128 347±124
VEFG (pg/mL)* 378±295 424±323 337±263
IL-6 (pg/mL) 15.5±20.4 16.6±24.8 14.9±15.9
NTproBNP (pg/mL) 6929±7014 8121±8526 5453±4262
HF, heart failure; SHF, systolic heart failure; HF-PSF, heart failure with preserved systolic function; PF, plasma fibrinogen; SA, sialic acid; CRP,
C-reactive protein; vWF, von Willebrand factor; VEGF, vascular endothelial growth factor. No significant differences were observed in any of
the comparisons. Differences SHF vs HF-PSF, *P<0.1.
Table 4.  Correlations upon hospital admission.
Total HF (n=131) SHF (n=62) HF-PSF (n=69)
SA-EDD -0.219* 0.220# -0.375*
SA-HB -0.210* -0.330* -0.078#
NTproBNP-creatinine 0.408* 0.471* 0.441#
Creatinine-HB -0.311** -0.384* -0.278*
HF, heart failure; SHF, systolic heart failure; HF-PSF, heart failure with preserved systolic function; SA, syalic acid; EDD, end diastolic diame-
ter; HB, hemoglobin; sPAP, systolic pulmonary artery pressure. Differences SHF vs HF-PSF,  #P<0.1. *P<0.05. **P<0.001.
Table 2. Treatment upon hospital admis-
sion in both groups.
SHF  HF-PSF 
(n=62) (n=69)
IECA/ARA-II 53.4 41.8
Beta-blockers 29.3 22.4
Antialdosteronics 29.3 22.4
ASA* 46.6 28.4
Anticoagulants* 24.1 44.8
Nitrates 27.6 17.9
Calcium antagonists* 15.5 34.3
Digoxin* 15.5 35.8
Furosemide 56.9 53.7
Insulin 10.3 16.4
Statins# 36.2 20.9
Allopurinol 8.6 3
SHF, systolic heart failure; HF-PSF, heart failure with preserved sys-
tolic function. All the values are expressed as percentages. #P<0.1.
*P<0.05.Clinical Investigation
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EF has not been clearly determined, as there
are  many  studies  providing  contradictory
data.28,29 In  our  case,  no  relationship  was
observed in IL-6 whether the EF was higher or
lower than 45%.  
In HF, oxygen supply to tissue is reduced.
This stimulates new vessel formation at the
tissue level. VEGF is an angiogenesis marker
believed to be involved in the physiopathology
of HF; it also has prognostic value. VEGF levels
are increased in stable HF patients in compar-
ison with controls.15 From all the markers ana-
lyzed, this is the only one in which a signifi-
cant tendency was found. Thus, patients with
SHF have slightly greater values, which may
indicate that these patients present more tis-
sue  hypoxia  and  more  angiogenic  prolifera-
tion. BNP and its precursor NTproBNP are the
most commonly used markers in HF. We ana-
lyzed NTproBNP as its determination was eas-
ier to obtain than the brain natriuretic peptid.
Both  markers  have  a  significant  diagnostic
and prognostic value.30,31 In stable HF patients,
those with depressed EF present higher values
of these peptides than patients with preserved
EF.8 Iwanaga et al.32 found that in patients with
symptomatic HF, BNP was higher in those with
an EF below 50%. However, the functional sta-
tus of 68% of these patients was below II. In
our study, all the patients presented a clear
deterioration  of  the  functional  status  (func-
tional class ≥ III), and in that context, no dif-
ferences  were  observed  in  the  BNP  and
NTproBNP values regarding the type of HF.
In patients with stable HF, multiple correla-
tions between the different IM and echocardio-
graphic  and  clinical  parameters  were  estab-
lished. SA negatively correlated with the end-
diastolic diameter in patients with HF-PSF, and
with hemoglobin in patients with SHF. As no
explanation  has  been  found  for  this,  it  is
thought to be a casual correlation. It is logical
indeed that NTproBNP was found to be higher
as  creatinine  increased  and  as  hemoglobin
decreased.  Renal  elimination  of  NTproBNP
causes patients with renal failure to present an
increase in its values. In addition, it has been
proven that anemia acts as an aggravating fac-
tor; therefore, it is normal that NTproBNP con-
centrations in patients with anemia are high-
er.  This  study  has  several  limitations.
Recruiting  patients  only  admitted  to  the
Cardiology Unit could have biased the sample.
Our hospital has other units with HF patients,
but  these  are  only  those  less  symptomatic.
Perhaps  in  our  sample  there  is  a  profile  of
patients with advanced HF. Moreover, a control
group has not been established, but we believe
that there are many studies in the literature in
which the normal range of the analyzed IM has
been established. Therefore, these limitations
do not invalidate the study results. 
Conclusions
The main conclusion of this work is that, in
the  acute  phase  of  HF,  no  differences  are
observed in the analyzed IM regarding the type
of  HF  (SHF  vs HF-PSF).  Further  long-term
studies are needed in order to determine when
differences in patients with stable HF appear,
and what prognostic value these differences
may have.
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